VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | DARE: dara for R/R myeloma with renal impairment

Efstathios Kastritis, MD, of the University of Athens School of Medicine, Athens, Greece, discusses the efficacy and safety of daratumumab (dara) with dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma and severe renal impairment as evaluated in the DARE study (NCT03450057). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter